DTB Podcast
The Drug and Therapeutics Bulletin (DTB) Podcast is your source for practical, independent, and evidence-based information on drugs, medication, and prescribing. Join the Editor-in-Chief and Deputy Editor of DTB each mon...
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Based on the show's feed history.
Built from
By chart position
- 🇳🇬NG · Medicine#732K to 18K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
2K to 18K🎙 Sporadic cadence·188 episodes·Last published 6d ago - Monthly Reach
Unique listeners across all episodes (30 days)
2K to 18K🇺🇸71%🇳🇬29% - Active Followers
Loyal subscribers who consistently listen
800 to 7.2K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 10/22/26 | When doctor becomes patient: levelling up the medical hierarchy | The perspective on medical care changes when the doctor becomes a patient. In the October episode, host Dr Hannah Harris (DTB's Clinical Editor and GP) speaks with the newly appointed Editor-in-Chief, Dr Gordon Mallarkey, to introduce themselves to the DTB podcast listeners and discuss the latest edition of the journal. Hannah summarises her editorial about doctor-patient communication, reflecting on medical gaslighting and her personal experience as a breast cancer patient.They also discuss a drug review on Inbrija, an inhaled powder form of levodopa, used to treat intermittent 'OFF' motor episodes in Parkinson’s disease, and conclude with a review of spasticity management, covering non-pharmacological, oral, injectable, and surgical options. Read the issue on our website: https://dtb.bmj.com/content/64/10. We would love to hear from you with comments or questions via email ([email protected]), or you can find us on X with the handle @DTB_BMJ, and also LinkedIn and Facebook under “Pharmacy at BMJ Group”. The DTB Podcast is hosted by Hannah Harris. It is produced by Hannah Harris and Letícia Amorim. It is edited by Letícia Amorim. | 14m 58s | ||||||
| 9/29/26 | When medicines cause harm: learning from the DES disaster | The DTB podcast returns with a new format, and a new host: Dr Hannah Harris, urgent care GP and Clinical Editor of DTB. In this episode, Hannah is joined by Professor Barbara Mintzes and Carol Devine, a patient and second-generation victim of Diethylstilbestrol (DES), to examine the long-term, multigenerational impacts of this synthetic oestrogen prescribed in pregnancy to prevent miscarriage from the 1940s to 1980s. They discuss why DES continued to be prescribed despite early proof of inefficacy and harm, Carol’s personal health struggle as a "DES Daughter," and the ongoing fight for government recognition and patient care. This episode also highlights key clinical updates from the September issue of the Drug and Therapeutics Bulletin, including a commentary by the new Editor-in-Chief, Dr Gordon Mallarkey, on precision medicine in COPD, non-hormonal treatments for polyendocrine metabolic ovarian syndrome, diagnosis of spasticity, and continuous glucose monitoring in type 2 diabetes. Read the issue on our website: https://dtb.bmj.com/content/64/9. We would love to hear from you with comments or questions via email ([email protected]), or you can find us on X with the handle @DTB_BMJ, and also LinkedIn and Facebook under “Pharmacy at BMJ Group”. The DTB Podcast is hosted by Hannah Harris. It is produced by Hannah Harris and Letícia Amorim. It is edited by Letícia Amorim. | 35m 25s | ||||||
| 3/23/26 | Understanding clinical significance, and the new epinephrine nasal spray | In this podcast accompanying the March 2026 issue of the DTB (https://dtb.bmj.com/content/64/3), Syba Sunny (DTB Clinical Editor) is joined by Shivali Fulchand (Editorials and Education editor at The BMJ). Syba and Shivali discuss this month’s editorial on clinically important differences (https://dtb.bmj.com/content/64/3/34) and talk about why this is such an important topic. Then they go on to talk through the DTB’s drug review on the new adrenaline nasal spray that’s been formulated for the treatment of anaphylaxis (https://dtb.bmj.com/content/64/3/36). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us, please email [email protected]. Thank you for listening. | 18m 30s | ||||||
| 2/3/26 | GLP-1 drugs, reducing sedative use, and a thank you | In this podcast accompanying the February 2026 issue of the DTB (https://dtb.bmj.com/content/64/2), Syba Sunny (DTB Clinical Editor) is joined by Julian Treadwell (DTB Associate Editor). Syba and Julian start by talking about this month’s ‘thank you’ editorial (https://dtb.bmj.com/content/64/2/18) before delving into the hot topic of GLP-1 drugs for the treatment of obesity, which is the subject of a DTB review article that summarises what is known about their benefits and harms (https://dtb.bmj.com/content/64/2/19). Finally, they discuss an intervention to reduce sedative use in patients who have been taking these drugs for a long time (https://dtb.bmj.com/content/64/2/25). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us, please email [email protected]. Thank you for listening. | 29m 07s | ||||||
| 1/6/26 | Disinformation and misinformation, AI in primary care and antidepressant tapering | In this podcast accompanying the January 2026 issue of the DTB (https://dtb.bmj.com/content/64/1), Syba Sunny (DTB Clinical Editor) is joined by Tom Nolan, an NHS general practitioner and Clinical Editor at BMJ Medicine. Syba and Tom first talk through this month’s editorial on disinformation and misinformation (https://dtb.bmj.com/content/64/1/2), and discuss ways to combat these in medicine. They then provide an overview of a DTB Forum article, which explains the benefits of taking people off antidepressants using the hyperbolic tapering method (https://dtb.bmj.com/content/64/1/3). The episode ends with Tom sharing his thoughts about the role of artificial intelligence (AI) in primary care. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us, please email [email protected]. Thank you for listening. | 20m 35s | ||||||
| 12/3/25 | Prevention in primary care, elinzanetant for menopause, and a farewell to David. | In this podcast accompanying the December issue of the DTB (https://dtb.bmj.com/content/63/12), David Phizackerley (DTB Editor) is joined by Syba Sunny (Clinical Editor). David and Syba discuss this month’s editorial, written by Julian Treadwell, academic GP and DTB editorial board member, which delves into the challenges of prioritising preventative medicine in primary care (https://dtb.bmj.com/content/63/12/178). They then talk about a review article that provides an overview of the new drug elinzanetant, a non-hormonal treatment for vasomotor symptoms associated with menopause (https://dtb.bmj.com/content/63/12/182). Finally, the journal bids an emotional farewell to David, who is retiring after many good years at the DTB. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us, please email [email protected]. Thank you for listening. | 16m 14s | ||||||
| 11/3/25 | Medicines - but at what cost, direct penicillin allergy challenge, and prescribing mistakes | In this podcast accompanying the November issue of DTB (https://dtb.bmj.com/content/63/11) David Phizackerley (DTB Editor) is joined by Syba Sunny (DTB Clinical Editor). David and Syba discuss the editorial that argues that NHS budgets should not be used to ensure that pharmaceutical companies invest in the UK (https://dtb.bmj.com/content/63/11/162). They talk about a DTB Select article that summarises a systematic review and meta-analysis of trials that assessed patients with a reported penicillin or beta-lactam allergy who underwent direct oral penicillin challenge (https://dtb.bmj.com/content/63/11/163). They finish by discussing the main article that explores the intersection of medication errors, prescribing errors, harms resulting from the use of medicines and some legal consequences (https://dtb.bmj.com/content/63/11/168). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 20m 12s | ||||||
| 10/1/25 | Orphan drugs, allopurinol and CVD, mavacamten for obstructive hypertrophic cardiomyopathy | In this podcast accompanying the October issue of DTB (https://dtb.bmj.com/content/63/10) David Phizackerley (DTB Editor) is joined by Julian Treadwell (DTB Associate Editor). David and Julian discuss the editorial that highlights a few of the challenges associated with the introduction of an orphan medicine into clinical practice (https://dtb.bmj.com/content/63/10/146). They talk about a DTB Select article that summarises a randomised clinical trial that assessed the effect of allopurinol on cardiovascular outcomes in people with ischaemic heart disease who did not have gout (https://dtb.bmj.com/content/63/10/147). They finish by discussing the main article that provides an overview of the evidence for mavacamten (▼Camzyos) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults (https://dtb.bmj.com/content/63/10/150). Links GP Evidence: https://gpevidence.org/ Preventing Overdiagnosis 2025 International Conference: https://www.cebm.ox.ac.uk/preventing-overdiagnosis Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 30m 14s | ||||||
| 9/5/25 | Antibiotic susceptibility reports, deprescribing, and heart failure drugs | In this podcast accompanying the September issue of DTB (https://dtb.bmj.com/content/63/9), David Phizackerley (DTB Editor) is joined by Syba Sunny (DTB Clinical Editor). David and Syba discuss the editorial that highlights changes to antibiotic susceptibility reports, and in particular, the change to the 'I' classification from 'intermediate' to 'susceptible, increased exposure’ (https://dtb.bmj.com/content/63/9/130). They talk about a DTB Select article that summarises an evidence review of deprescribing interventions in primary care and the importance of collaborative multidisciplinary teams, education and training, and shared-decision making (https://dtb.bmj.com/content/63/9/131). They finish by discussing the main article that provides an overview of pharmacological management of chronic heart failure with reduced ejection fraction and the four main groups of drugs that form the four pillars of treatment (https://dtb.bmj.com/content/63/9/133). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 17m 53s | ||||||
| 7/31/25 | AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease | In this podcast accompanying the August issue of DTB (https://dtb.bmj.com/content/63/8), David Phizackerley (DTB Editor) is joined by James Cave (former DTB Editor-in-Chief). David and James discuss an editorial generated by artificial intelligence (AI) (https://dtb.bmj.com/content/63/8/114) which looks at the role of AI in publishing. They talk about a DTB Forum article (https://dtb.bmj.com/content/63/8/115) that explores some of the practical problems of implementing drug safety alerts. A DTB Select article (https://dtb.bmj.com/content/63/8/117) provides an overview of a double-blind, randomised, placebo-controlled trial of tirzepatide for weight reduction in people without diabetes. They finish by reviewing the main article (https://dtb.bmj.com/content/63/8/118) that provides an overview of the evidence for lecanemab for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease. LinkBMJ policy on AI use: https://www.bmj.com/content/ai-use Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 38m 47s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/1/25 | National asthma guidelines, bisoprolol for COPD and abaloparatide for osteoporosis | In this podcast accompanying the July issue of DTB (https://dtb.bmj.com/content/63/7), David Phizackerley (DTB Editor) is joined by Syba Sunny (Clinical Editor). David and Syba discuss the editorial (https://dtb.bmj.com/content/63/7/98) which focuses on some key changes in the new national asthma guideline and the implications for patients and healthcare professionals. A DTB Select article (https://dtb.bmj.com/content/63/7/99) provides an overview of a double-blind randomised placebo-controlled trial that assessed whether bisoprolol reduced the number of exacerbations in people with COPD. The main article (https://dtb.bmj.com/content/63/7/103) is an overview of abaloparatide, which is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. The podcast begins with a discussion about ideas for new articles for DTB and the therapeutic areas currently under consideration. If you have a suggestion for an article that you would like DTB to cover, please email details to [email protected]. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 22m 52s | ||||||
| 6/3/25 | Identifying VTE in early pregnancy, gabapentinoids and COPD, managing ADHD | In this podcast accompanying the June issue of DTB, David Phizackerley (DTB Editor) is joined by Julian Treadwell (DTB Associate Editor) and Laurence Leaver (GP). David and Julian start by discussing the editorial - https://dtb.bmj.com/content/63/6/82 - which highlights some of the challenges in preventing VTE in early pregnancy. They also talk about a cohort study - https://dtb.bmj.com/content/63/6/84 - that assessed whether gabapentinoid use was associated with severe exacerbations among patients aged >55 years with chronic obstructive pulmonary disease (COPD). In the second half of the podcast, Julian talks to Laurence about two articles - https://dtb.bmj.com/content/63/5/74 and https://dtb.bmj.com/content/63/6/85 - he wrote on managing ADHD in adults. Their discussion includes issues relating to diagnosis, effectiveness of medication, starting and titrating medication and some of the common adverse effects associated with medication. Both articles are currently free to access on the DTB website. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 39m 30s | ||||||
| 5/9/25 | The polypill revisited, cytisinicline for vaping cessation and a new co-host | In this podcast accompanying the May issue (https://dtb.bmj.com/content/63/5) of DTB, David Phizackerley (DTB Editor) welcomes Syba Sunny (DTB Clinical Editor) to the podcast. Syba provides an overview of her role with DTB, discusses her previous work as a Consultant Microbiologist and talks about areas of interest for future DTB articles. The editorial (https://dtb.bmj.com/content/63/5/66) discusses a paper in The BMJ which proposed offering a polypill containing rosuvastatin, hydrochlorothiazide, amlodipine and losartan to all people in the UK over the age of 50 years to reduce the risk of heart attacks and strokes. A DTB Select item (https://dtb.bmj.com/content/63/5/68) summarises the results of a small study that assessed whether cytisinicline (cytisine) plus behavioural support was more effective than behavioural support alone for vaping cessation. The main article (https://dtb.bmj.com/content/63/5/74) is the first of two articles on the medical management of ADHD and there will be a longer discussion and an interview with the author in the June podcast. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 19m 28s | ||||||
| 4/2/25 | Misuse of female empowerment to sell tests and treatments, triptan safety, use of ACEI or AIIRA in CKD | In this podcast recorded in early March, David Phizackerley (DTB Editor-in-Chief) and James Cave (DTB Editor-in-Chief Emeritus) provide an overview of the April 2025 issue of DTB. The editorial discusses concerns over the use of feminist empowerment messages to sell tests and treatments - https://dtb.bmj.com/content/63/4/50. A DTB Select item summarises the results of an observational study that assessed the association between initiation of a triptan and the risk of myocardial infarction or stroke - https://dtb.bmj.com/content/63/4/51. The main article provides an overview of initiating angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists in adults with CKD, highlighting current guideline recommendations and providing a practical approach to dealing with the challenges associated with their use - https://dtb.bmj.com/content/63/4/54. Links Health Innovation Network: https://thehealthinnovationnetwork.co.uk/news/launch-of-new-game-changing-guide-to-tackle-overprescribing-and-support-governments-shifts-to-prevention-and-community/ Tackling overprescribing report: https://thehealthinnovationnetwork.co.uk//wp-content/uploads/2025/02/Health-Innovation-Network-Polypharmacy-Guide-Feb-2025.pdf GP Evidence: (https://gpevidence.org/) Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 28m 17s | ||||||
| 3/3/25 | Paying the price, liver problems with fezolinetant, systemic anticancer treatments | In this podcast recorded in early February, David Phizackerley and Julian Treadwell (DTB Associate Editor) provide an overview of the March 2025 issue of DTB. Julian talks about his work as an academic GP based at Bristol University. He explains why and how he developed the GP Evidence website (https://gpevidence.org/) as a resource for health professionals to use as part of a shared decision making process, and talks about the importance of providing patients with information on the absolute benefits and harms of different treatment options for long-term conditions. The editorial discusses a paper published in The Lancet on the population-health impact of new drugs recommended by NICE and highlights the tension between NICE's role in ensuring that treatments are a cost-effective use of taxpayers’ money and its role in championing the for-profit life-sciences - https://dtb.bmj.com/content/63/3/34. A DTB Select item summarises safety alerts issued by the US Food and Drug Administration and the European Medicines Agency on liver problems associated with fezolinetant (▼Veoza), a drug licensed for the treatment of moderate-to-severe vasomotor symptoms associated with the menopause - https://dtb.bmj.com/content/63/3/36. The main article provides an overview of systemic anticancer treatments and conventional cytotoxic drugs - https://dtb.bmj.com/content/63/3/37. Links GP Evidence (https://gpevidence.org/) Naci H, Murphy P, Woods B, et al. Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. The Lancet 2025;405:50–60. (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02352-3/fulltext) Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 31m 57s | ||||||
| 1/27/25 | Prioritising shared decision making, remission from type 2 diabetes, gefapixant for cough | In this podcast recorded in early January, David Phizackerley provides a brief overview of the February 2025 issue of DTB. The editorial discusses the importance of shared decision making and calls on guideline developers to produce patient decision aids to accompany their guidance - https://dtb.bmj.com/content/63/2/18. A DTB Select item summarises a study that evaluated implementation of NHS England’s type 2 diabetes path to remission programme - https://dtb.bmj.com/content/63/2/19. The authors of a DTB Commentary article review a UK primary care study which reported that treatment with antihypertensive medicines in older people with complex health needs was associated with an increased risk of acute kidney injury (AKI) and a short-term increased risk of falls - https://dtb.bmj.com/content/63/2/20. The main article explores the evidence for gefapixant in the treatment of refractory or unexplained chronic cough in adults - https://dtb.bmj.com/content/63/2/22. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 9m 08s | ||||||
| 12/30/24 | PILs: all harms and no benefits, Irish College of GPs end pharma funding, Ryeqo for fibroids | In this podcast recorded in early December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2025 issue of DTB. They provide an overview of the editorial that questions whether it is time for the medicine Patient Information Leaflet (PIL) to include information on the impact of a medicine on clinical outcomes - https://dtb.bmj.com/content/63/1/2. They talk about a recent announcement from the Irish College of GPs that it is phasing out sponsorship from pharmaceutical companies as evidence suggests that ‘engagement between pharmaceutical companies and prescribers is associated with inappropriately increased prescribing rates, lower prescribing quality and increased prescription costs’ - https://dtb.bmj.com/content/63/1/3. The main article provides an overview of Ryeqo (relugolix, estradiol and norethisterone acetate) for the treatment of moderate to severe symptoms of uterine fibroids - https://dtb.bmj.com/content/63/1/6. The podcast ends with a farewell to James, who is stepping down as Editor-in-Chief after more than 12 years. James reflects on his time as a doctor, GP and Editor of DTB. Other links: Is ASCOT all it's cracked up to be? https://www.bmj.com/content/331/7523/1023.1 Don't lose your head over ASCOT https://www.bmj.com/content/331/7523/1022.1 | 29m 00s | ||||||
| 11/28/24 | When it comes to drugs, sex matters; menopausal HT and dementia; daridorexant for sleep | In this podcast recorded in early November, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the December issue of DTB. They provide an overview of the editorial that discusses the need to record the sex and gender of all participants in clinical trials and the importance of recognising diversity and inclusivity in clinical research - https://dtb.bmj.com/content/62/12/178. They talk about a commentary article that addresses claims made in a systematic review that menopausal HT may support neurological function and reduce the risk of Alzeheimer's disease - https://dtb.bmj.com/content/62/12/179. The main article provides an overview of daridorexant for the management of chronic sleep - https://dtb.bmj.com/content/62/12/183. They begin by providing an update on the NICE guidance for tirzepatide and highlighting the publication of a toolkit for repeat prescribing in general practice. Other related links NICE guidance on tirzepatide: https://www.nice.org.uk/guidance/gid-ta11156/documents/html-content-10 Repeat prescribing toolkit: https://www.rpharms.com/resources/repeat-prescribing-toolkit | 27m 53s | ||||||
| 10/30/24 | Supporting obesity treatment, major bleeds with anticoagulants and SSRIs, equity in COPD care | In this podcast recorded in early October, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the November issue of DTB. They provide an overview of the editorial that discusses the need to support people taking drugs to help with weight loss: "Providing the drug is only one part of the process and if the other elements are not available to support people with obesity the full benefits of these expensive treatments will not be realised" - https://dtb.bmj.com/content/62/11/162. They talk about the results of an observational study that assessed the risk of major bleeds with concomitant use of selective serotonin reuptake inhibitors (SSRIs) and oral anticoagulants - https://dtb.bmj.com/content/62/11/164. The main article discusses equity of care in the management of COPD and that those more at risk of COPD are also more likely to experience barriers to care - https://dtb.bmj.com/content/62/11/165. They begin by highlighting two articles* in the BMJ that consider the problem of conflicts of interest. *Fabbri A, Grundy Q. Protecting early career physicians from commercial influence. BMJ. 2024 Sep 9;386:q1939. (https://www.bmj.com/content/386/bmj.q1939) McCartney M. Transparency as a means to conquer conflicts of interest is illusory. BMJ. 2024 Sep 24;386:q2092. (https://www.bmj.com/content/386/bmj.q2092) Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 24m 31s | ||||||
| 9/25/24 | (Un)common sense in oncology, DOACs in device-detected AF, and hypertension in the elderly | In this podcast recorded in early September, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the October issue of DTB. They discuss the editorial that highlights the work of the Common Sense in Oncology movement and its aim "to counteract the trend towards irrational, industry-designed, profit-driven cancer drug development" - https://dtb.bmj.com/content/62/10/146. They talk about the results of a systematic review and meta-analysis of two randomised controlled trials that assessed the effect of treating people who have device-detected subclinical atrial fibrillation (AF) with a direct oral anticoagulant - https://dtb.bmj.com/content/62/10/147. The main article discusses the management of hypertension in older people - https://dtb.bmj.com/content/62/10/149. They begin by highlighting an article* that considers the challenges associated with the introduction of new drugs for the treatment of Alzheimer's disease. *Walsh S, Merrick R, Milne R, et al. Considering challenges for the new Alzheimer's drugs: clinical, population, and health system perspectives. Alzheimers Dement. 2024. doi: 10.1002/alz.14108. [Epub ahead of print 4 Aug 2024].https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14108 Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 19m 49s | ||||||
| 9/6/24 | Medicines optimisation measures, warfarin-tramadol interaction and icosapent ethyl | In this podcast recorded in early August, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the September issue of DTB. They discuss the editorial (https://dtb.bmj.com/content/62/9/130) that highlights some of the challenges associated with NHS England's national medicines optimisation measures for Integrated Care Boards. They talk about the MHRA's recent safety alert on the risk of an interaction between tramadol and warfarin (https://dtb.bmj.com/content/62/9/131), which was prompted by a coroner's prevention of future deaths report (summarised in a DTB article in March https://dtb.bmj.com/content/62/3/36). The main article reviews the evidence for icosapent ethyl for cardiovascular risk reduction (https://dtb.bmj.com/content/62/9/135). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 22m 48s | ||||||
| 7/29/24 | Psychotropic medicines in children, warfarin vs DOAC in old age, and fezolinetant in menopause | In this podcast recorded in early July, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) continue to ignore political and sporting events and talk about the August issue of DTB. They discuss the editorial that highlights the growth in the use of psychotropic medication in children and young people and some of the challenges associated with this trend. They talk about a study that assessed the harms of changing frail older people with AF from warfarin to a DOAC. The main article is an overview of the evidence for fezolinetant for the treatment of menopausal vasomotor symptoms. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 20m 19s | ||||||
| 7/1/24 | Propranolol and its risk in overdose and managing COPD exacerbations | In this podcast recorded in early June, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) ignore the UK general election, the T20 cricket world cup and the European football championship and talk about the July 2024 issue of DTB. They discuss the editorial that highlights trial data showing that dupilumab had a modest effect on reducing COPD exacerbations, and question whether more drugs or greater investment in pulmonary rehabilitation and smoking cessation services are a better use of resources. They review a coroner's prevention of future deaths report that highlights the need to raise awareness of the dangers of propranolol overdose. The main article discusses the management of exacerbations of COPD in primary care. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email [email protected]. Thank you for listening. | 17m 19s | ||||||
| 5/29/24 | Diagnostic imaging and shielding, sinusitis, antibiotics and coloured snot, ritlecitinib | In this podcast recorded in early May, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the June 2024 issue of DTB. They discuss the editorial that highlights changes to the use of gonadal and fetal shielding for diagnostic imaging (see link). They review the results of a study that assessed the benefit of antibiotics for treating acute sinusitis in children aged 2-11 years. The main article considers the evidence for ritlecitinib, a Janus kinase enzyme inhibitor that is licensed for the treatment of severe alopecia areata in adults and adolescents aged ≥12 years. They begin the podcast by discussing newspaper headlines generated by an international conference on obesity. Link https://www.bir.org.uk/education-and-events/patient-shielding-guidance.aspxPlease subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email [email protected]. Thank you for listening. | 23m 05s | ||||||
| 4/25/24 | Medicines and global warming, donanemab for AD, and cytisine for smoking cessation | In this podcast recorded in early April, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the May 2024 issue of DTB. They discuss the editorial that highlights the effect medicines have on greenhouse gas emissions and the need to consider the environmental impact of all aspects of the patient care pathway (https://dtb.bmj.com/content/62/5/66). They review the results of a study that assessed the effect of donanemab on early symptomatic Alzheimer's disease (https://dtb.bmj.com/content/62/5/67). The main article considers the evidence for cytisine, a nicotine receptor partial agonist, that has recently been licensed to facilitate quitting smoking (https://dtb.bmj.com/content/62/5/71). They begin by highlighting some useful resources relating to the safe use of valproate. Other links: https://www.england.nhs.uk/patient-safety/sodium-valproate/ https://www.england.nhs.uk/publication/decision-support-tool-is-valproate-the-right-epilepsy-treatment-for-me/ https://www.gov.uk/government/collections/valproate-safety-measures https://www.gov.uk/guidance/valproate-use-by-women-and-girls Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email [email protected]. Thank you for listening. | 26m 02s | ||||||
Showing 25 of 188
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart history for DTB Podcast
Peaked at #73 in NG, currently #73 in NG.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| NG | — | #73 | #73 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.